The Program in Vascular Biology, Boston Children's Hospital, Boston, Massachusetts.
Department of Surgery, Boston Children's Hospital, Boston, Massachusetts.
Mol Cancer Res. 2017 Nov;15(11):1608-1622. doi: 10.1158/1541-7786.MCR-17-0188. Epub 2017 Aug 1.
ADAM12, (isintegrin nd etalloproteinase domain-containing protein 12), is upregulated in epithelial cancers and contributes to increased tumor proliferation, metastasis, and endocrine resistance. However, its role in tumor angiogenesis is unknown. Here, we report that ADAM12 is upregulated in the vessels of aggressive breast tumors and exerts key regulatory functions. ADAM12 significantly increases bFGF-mediated angiogenesis and ADAM12 levels are upregulated in tumors that have undergone a switch to the angiogenic phenotype. Importantly, ADAM12-overexpressing breast tumors display a higher microvessel density (MVD). Our goal was to identify the mechanisms by which tumor-associated ADAM12 promotes angiogenesis. ADAM12 expression in breast tumor cells correlated with a significant upregulation of proangiogenic factors such as VEGF and MMP-9 and downregulation of antiangiogenic factors such as Thrombospondin-1 (THBS1/TSP1) and Tissue Inhibitor of Metalloproteinases-2 (TIMP-2). Co-culture with ADAM12-expressing tumor cells promoted endothelial cell (EC) recruitment and capillary tube formation. Conversely, downregulation of endogenous ADAM12 in breast cancer cell lines resulted in reduction of pro-angiogenic factors and EC recruitment. These ADAM12-mediated effects are driven by the activation of EGFR, STAT3 and Akt signaling. Blockade of EGFR/STAT3 or silencing of ADAM12 reversed the proangiogenic tumor phenotype, significantly downregulated pro-angiogenic mitogens and reduced EC recruitment. In human breast cancer tissues, ADAM12 expression was significantly positively correlated with pro-angiogenic factors including VEGF and MMP-9 but negatively associated with TSP1. These novel findings suggest that ADAM12 regulates EC function and facilitates a proangiogenic microenvironment in a STAT3-dependent manner. A combined approach of targeting ADAM12 and STAT3 signaling in breast cancer may represent a promising strategy to inhibit tumor neovascularization. .
ADAM12(整合素和金属蛋白酶结构域蛋白 12)在上皮癌中上调,并促进肿瘤增殖、转移和内分泌抵抗。然而,其在肿瘤血管生成中的作用尚不清楚。在这里,我们报告 ADAM12 在侵袭性乳腺癌的血管中上调,并发挥关键的调节功能。ADAM12 显著增加 bFGF 介导的血管生成,并且 ADAM12 水平在经历向血管生成表型转变的肿瘤中上调。重要的是,过表达 ADAM12 的乳腺癌肿瘤显示更高的微血管密度(MVD)。我们的目标是确定肿瘤相关 ADAM12 促进血管生成的机制。乳腺癌细胞中 ADAM12 的表达与促血管生成因子如 VEGF 和 MMP-9 的显著上调以及抗血管生成因子如血小板反应蛋白-1(THBS1/TSP1)和金属蛋白酶组织抑制剂-2(TIMP-2)的下调相关。与表达 ADAM12 的肿瘤细胞共培养促进了内皮细胞(EC)的募集和毛细血管管形成。相反,乳腺癌细胞系中内源性 ADAM12 的下调导致促血管生成因子和 EC 募集减少。这些 ADAM12 介导的效应是由 EGFR、STAT3 和 Akt 信号的激活驱动的。EGFR/STAT3 阻断或 ADAM12 沉默逆转了促血管生成的肿瘤表型,显著下调了促血管生成有丝分裂原并减少了 EC 的募集。在人类乳腺癌组织中,ADAM12 的表达与包括 VEGF 和 MMP-9 在内的促血管生成因子呈显著正相关,但与 TSP1 呈负相关。这些新发现表明,ADAM12 以 STAT3 依赖的方式调节 EC 功能并促进促血管生成的微环境。在乳腺癌中靶向 ADAM12 和 STAT3 信号的联合方法可能代表抑制肿瘤新生血管形成的一种有前途的策略。